Needham Maintains Buy on Axsome Therapeutics, Lowers Price Target to $150

Benzinga · 06/09 12:15
Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $153 to $150.